ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1879

Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023

Mario Bautista-Vargas1, Adrian Romero-Ocampo2, Juan José Pino Vélez3, juliana Muñoz-Bedoya4 and Diego Rosselli5, 1Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, 2Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, 3Universidad de Antioquia, Envigado, Antioquia, Colombia, 4Universidad Corpas, Bogotá, Colombia, 5Pontificia Universidad Javeriana, Bogotá, Colombia

Meeting: ACR Convergence 2024

Keywords: autoantigens, autoimmune diseases, Demographics, Epidemiology, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly accessible. A descriptive analysis was conducted, emphasizing demographic variables of the Colombian population to estimate the prevalence of Relapsing Polychondritis based on consultation records from January 2017 to December 2022.

Methods: An observational-descriptive cross-sectional study utilized the International Classification of Diseases (ICD-10) codes, specifically the diagnosis code for Relapsing Polychondritis (M941), to analyze variables including sex, age, and prevalence distribution.

Results: From 2018 to 2022, Colombia registered a total of 6,111 patients diagnosed primarily with relapsing polychondritis, revealing varying distributions by sex and age. The overall prevalence was 11.51 cases per 100,000 individuals. The highest prevalence occurred in the 50 to 59 age group, with rates of 20.28 per 100,000 for women and 7.81 per 100,000 for men. Conversely, the lowest prevalence was observed in those aged 80 years or older, with rates of 8.66 per 100,000 for women and 4.25 per 100,000 for men (Table 1). Women exhibited a higher prevalence compared to men (14.91 versus 7.72 per 100,000), with a female-to-male ratio of 1.94:1. Notably, this ratio expanded to 2.6:1 in the 50-59 age group (Figure 1).

Epidemiological analysis revealed regional disparities in relapsing polychondritis prevalence across Colombia, particularly noteworthy in the Archipelago of San Andrés, Providencia, and Santa Catalina, where a prevalence of 13.4 was reported among females compared to an absence of cases among males. Similar asymmetries were observed in Amazonas and Vaupés departments, with zero prevalence among women and 3.8 and 7.3 per 100,000 among men, respectively.

Conclusion: This observational-descriptive cross-sectional study provides insights into the epidemiology of relapsing polychondritis in Colombia, highlighting regional variations and implications for diagnosis, treatment, and public health interventions. Limitations include potential under-registration due to diagnostic constraints inherent in the ICD-10 coding system. This study represents the first of its kind to report national prevalence data on relapsing polychondritis in a Latin American country.

Supporting image 1

Table 1. Number of patients registered with main diagnosis of relapsing polychondritis according to age group between 2018 _2022

The total patient’s column corresponds to patients seen in the ten-year period. Prevalence is calculated from the ratio per 100,000 patients seen during the same period.

Supporting image 2

Figure 1. Prevalence of relapsing polychondritis according to sex and age in Colombia, 2018_2022.


Disclosures: M. Bautista-Vargas: None; A. Romero-Ocampo: None; J. Pino Vélez: None; j. Muñoz-Bedoya: None; D. Rosselli: None.

To cite this abstract in AMA style:

Bautista-Vargas M, Romero-Ocampo A, Pino Vélez J, Muñoz-Bedoya j, Rosselli D. Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023 [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-relapsing-polychondritis-in-colombia-data-from-the-national-health-registry-2018-2023/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-relapsing-polychondritis-in-colombia-data-from-the-national-health-registry-2018-2023/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology